Treatment of Hyperhydrosis

This policy covers diagnosis and treatment options for hyperhidrosis, including topical aluminum chloride, oral anticholinergics, iontophoresis, intradermal botulinum toxin (with onabotulinumtoxinA the only FDA‑approved product for severe adult axillary hyperhidrosis), and surgical interventions (e.g., sympathectomy or axillary excision) for refractory cases. Coverage is focused on adults with primary focal hyperhidrosis (axillary, palmar, plantar) or select secondary/gustatory forms who meet specified criteria (≥6 months’ symptoms, functional impairment, HDSS severity, and prior inadequate response to topical agents for onabotulinumtoxinA); experimental/unproven therapies are excluded and all services are subject to member benefit plan limits and state regulations.

"Primary focal hyperhidrosis"

Sign up to see full coverage criteria, indications, and limitations.